Upstart, Compass, RingCentral And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones dropping around 70 points on Wednesday. Here are some big stocks recording gains in today’s session.
Nasdaq Surges Over 1%; US Inflation Falls In April
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 100 points on Wednesday.
12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers CTI BioPharma (NASDAQ:CTIC) stock rose 85.1% to $8.92 during Wednesday’s pre-market session. The company’s market cap stands…
Why CTI BioPharma Shares Are Trading Higher By 84%; Here Are 20 Stocks Moving Premarket
Gainers
Unique Fabricating, Inc. (NYSE: UFAB) gained 88.8% to $0.34 in pre-market trading after gaining around 4% on Tuesday.
European Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B
Swedish Orphan Biovitrum AB (OTC: BIOVF) has agreed to acquire CTI BioPharma (NASDAQ: CTIC) for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of
What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks
Incyte Corporation (NASDAQ: INCY) will report Q1 FY23 results on May 2.
Investor focus remains on the Opzelura launch, which has faced some hiccups over the first 18 months of launch and began to gain traction toward the end of 2022.
CTI BioPharma Corp. 13G Filing Shows Stonepine Capital Management, LLC Increases Stake In Co To 5.3%
1.
Names of Reporting Persons.
Stonepine Capital Management, LLC
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ______
(b)
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Needham Reiterates Buy on CTI BioPharma, Maintains $9 Price Target
Needham analyst Gil Blum reiterates CTI BioPharma (NASDAQ:CTIC) with a Buy and maintains $9 price target.
CTI BioPharma Q4 EPS $(0.14) Vs $(0.38) Last Year, Sales $21.10M Miss $23.67M Estimate
CTI BioPharma (NASDAQ:CTIC) reported quarterly losses of $(0.14). This is a 63.16 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $21.10 million